MetaVia

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on the bottom line, with a GAAP net loss of $5.3M vs. the $4.25M expected and GAAP EPS of -$0.90 vs. the -$0.82 consensus. While revenue remained at zero as expected for this clinical-stage firm, R&D expenses surged 50% YoY to $3.5M, primarily driven by the DA-1726 Phase 1 titration studies. A 'substantial doubt' going concern warning remains as cash reserves of $12.6M face an annualized burn rate exceeding $16M, necessitating further capital raises.